Research · Source update
Indirect study compares Zepbound with Wegovy HD
Source context: Read the linked original research or registry entry for study status and limitations.
Lilly presented an indirect comparison drawing on SURMOUNT-1 and STEP UP study data. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Lilly presented an indirect comparison drawing on SURMOUNT-1 and STEP UP study data. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly indirect weight-loss comparison, dated 2026-09-29.
What did the source report?
The company reported a 4.5 percentage-point greater weight loss estimate for Zepbound 15 mg versus Wegovy HD in its analysis. Lilly presented an indirect comparison across SURMOUNT-1 and STEP UP, estimating greater weight loss at a specified tirzepatide dose.
How should the results be interpreted?
Indirect comparisons cannot remove all differences between the original trial populations and protocols; this was not a randomized head-to-head trial. Different trial participants, missing data methods and durations can bias cross-trial comparisons, even when statistical adjustments are used.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
Treat comparisons across trials as less conclusive than direct randomization. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
Treat comparisons across trials as less conclusive than direct randomization.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-09-29. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly indirect weight-loss comparison ↗
Source event or update: 2026-09-29. Our interpretation is educational and does not replace medical or insurance advice.